Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug

Frank Vinluan / medcitynews - Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia,…

AI Summary: Merck announced a definitive deal to acquire Terns Pharmaceuticals for about $6.7 billion, gaining a promising leukemia drug candidate and bolstering its oncology pipeline. The transaction aims to combine Merck’s late‑stage development and commercialization capabilities with Terns’ targeted therapy assets to compete in hematologic malignancies.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

UCB acquires Candid for $2B to pursue T‑cell engager therapies / 22 days

Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 2 months

Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 7 wks

Pfizer’s $10.5B buy signals shifting oncology power toward China / 36 hrs

Eli Lilly acquires CrossBridge Bio in oncology deal up to $300M / 6 wks

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days

Gilead exercises options to accelerate oncology pipeline expansion / 7 wks